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Background:  Insulin  resistance  (IR) is known  to  be  a risk  factor  for coronary  artery  disease  (CAD).  We  aimed
to  evaluate  the  impact  of  IR  on  1-year  clinical  outcomes  in  non-diabetic  CAD  patients  who  underwent
percutaneous  coronary  intervention  (PCI)  with  drug-eluting  stents  (DESs).
Methods and  results:  A  total  of  229  consecutive  non-diabetic  CAD  patients  treated  with  DESs  were  enrolled.
Study  population  was  divided  into  IR group  [homeostasis  model  assessment  (HOMA)  index  ≥ 2.5,  n  =  54]
and non-IR  group  (HOMA  index  <  2.5,  n  =  175).  Baseline  clinical  and  procedural  characteristics  were  simi-
lar between  the  groups  except  higher  incidence  of  high-sensitivity  C-reactive  protein  and  lower  incidencerug-eluting stent of multivessel  disease  as  the target  vessel  in  the  non-IR  group.  There  was  a trend  toward  longer  restenosis
lesion length  in the  IR group  at 6 months  angiographic  follow  up but composite  major  clinical  outcomes
up  to  1  year  were  similar  between  the  two  groups.
Conclusions:  Despite  worse  trend  in  angiographic  outcomes  in the IR group  (HOMA  index ≥ 2.5),  it was
not  translated  into  worse  1-year  major  clinical  outcomes  following  PCI  with  DESs  as  compared  to the
non-IR group.
2  Jap©  201
ntroduction
Insulin resistance (IR) is deﬁned as decreased sensitivity and
esponsiveness to metabolic action of insulin to target organs. In
936 Himsworth suggested the ﬁrst concept of IR [1].  He found
ome diabetic patients who required more doses of insulin for blood
ugar control. He differentiated types of diabetes into insulin sen-
itive and insulin insensitive. IR with hyperinsulinemia is known to
e associated with hypertension, glucose intolerance, obesity, and
yslipoproteinemias of low high-density lipoprotein cholesterol
HDL-C) levels or hypertriglyceridemias, which are well-known
isk factors for coronary artery disease (CAD) [2].
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0,  Guro-dong, Guro-gu, Seoul 152-703, Rublic of Korea. Tel.: +82 2 2626 3020;
ax: +82 2 864 3062.
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There are some reports that high fasting-insulin level and IR
are also associated with in-stent restenosis in nondiabetics [3] and
studies have shown that IR is an independent predictor of early
restenosis after coronary stenting [4].
However, the impact of IR on major clinical outcomes following
percutaneous coronary intervention (PCI) in the drug-eluting stent
(DES) era is largely unknown.
Therefore we  conducted this study to evaluate the impact of
IR on 1-year major clinical outcomes in non-diabetic CAD patients
undergoing PCI with DESs.
Methods
Study populationWe  performed a retrospective observational analysis of 229 con-
secutive non-diabetic patients with CAD who underwent PCI with
DESs from January 2004 to June 2009 at the Cardiovascular Center,
Korea University Guro Hospital, Seoul, Korea. We  excluded patients
vier Ltd. All rights reserved.
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Table 1
Baseline clinical and laboratory characteristics.
Variable, n (%) IR (n = 54 pts,
23.6%)
Non-IR (n = 175
pts, 76.4%)
p-Value
Male 39 (72.2) 130 (74.3) 0.860
Age,  years 63.2 ± 12.4 64.0 ± 11.6 0.616
Current smoking 26 (49.1) 91 (52.6) 0.754
Hypertension 38 (70.4) 99 (56.6) 0.082
Dyslipidemia 9 (16.7) 37 (21.1) 0.563
Prior myocardial infarction 0 (0.0) 2 (1.1) 1.000
Prior CABG 0(0) 1(0.6) 1.000
Prior PCI 4 (7.4) 12 (6.9) 1.000
UA  21 (38.9) 86 (49.1) 0.213
STEMI 3 (5.6) 19 (10.9) 0.302
NSTEMI 9 (16.7) 18 (10.3) 0.229
Total cholesterol (mg/dL) 178.2 ± 47.6 173.4 ± 41.9 0.847
Triglyceride (mg/dL) 137.1 ± 74.9 133.1 ± 86.3 0.941
HDL-cholesterol (mg/dL) 44.0 ± 12.0 44.9 ± 12.9 0.403
LDL  cholesterol (mg/dL) 117.6 ± 41.4 112.9 ± 37.1 0.436
Insulin (m/mL)  18.2 ± 34.8 4.7 ± 2.7 0.002
Glucose (mg/dL) 106.2 ± 12.0 99.5 ± 13.2 0.474
HbA1c (U/mL) 5.8 ± 0.4 5.7 ± 0.6 0.258
HOMA-IR (mg/dL × U/mL) 3.6 ± 1.1 1.1 ± 0.7 0.000
Creatinine (mg/dL) 0.9 ± 0.3 1.0 ± 0.8 0.566
hs  CRP (mg/L) 5.4 ± 12.9 13.1 ± 34.8 0.015
Data are mean ± SD or number (%). IR, insulin resistance; CABG, coronary artery
bypass graft; Hb, hemoglobin; HDL, high-density lipoprotein; HOMA,  homeostasis
model assessment; hs CRP, high sensitivity C-reactive protein; LDL, low-density14 I.K. Hwang et al. / Journal o
ho were newly diagnosed with diabetes, treated for diabetes,
nd those who had high fasting glucose (>125 mg/dL) or glycated
emoglobin A1c level (>6.5%).
Patients’ baseline demographic characteristics, clinical char-
cteristics, medical history, and procedural data were collected.
ne-year major clinical outcome data were collected by interview-
ng at outpatient clinic, telephone interview, and interviewing at
he time of routine 6-month follow-up coronary angiography. All
atients gave informed consent according to a protocol approved
y the Ethics Committee in Korea University Guro Hospital.
lood sample and biochemical investigation
Blood sampling was done before PCI at fasting state in rou-
ine stable PCI. In cases of ST-elevation myocardial infarction
STEMI) undergoing primary PCI or non-STEMI undergoing early
nvasive strategy, blood sampling was done next day early
n the morning following adequate fasting. Samples were col-
ected from venous blood after overnight fasting and blood
hemistry was performed. Fasting plasma glucose and insulin
ere measured and other parameters including the concentra-
ions of serum total cholesterol, triglyceride, HDL-C, low-density
ipoprotein cholesterol (LDL-C), creatinine, and high-sensitivity C-
eactive protein (hsCRP) were measured. Insulin resistance was
alculated by the homeostasis model assessment of insulin resis-
ance (HOMA-IR), proposed by Matthews et al., whose formula
as: HOMA-IR (mg/dL × U/mL) = fasting glucose (mg/dL) × fasting
nsulin (U/mL)/405 [5].  There were no reports of standard of insulin
esistance at HOMA index in Koreans. We  used 2.5 as a cut-off point
or the analysis; HOMA index ≥ 2.5 was deﬁned as IR group and
OMA index < 2.5 was deﬁned as insulin sensitive group [6].
ercutaneous coronary intervention
Coronary angiography was performed by either femoral or
adial approach. Interventional procedure included percutaneous
ransluminal balloon angioplasty and subsequent DES implan-
ation. PCIs were performed after administration with weight-
djusted bolus of unfractionated heparin (UFH, 70–100 U/kg)
r combined administration of low molecular weight heparin
LMWH) and reduced dose of UFH (50 U/kg) during the procedure.
uring the procedure, patients received UFH to maintain the acti-
ated clotting time >250 s. Loading doses of aspirin (200–300 mg)
nd clopidogrel (300 or 600 mg)  were administered before the
rocedure and followed by aspirin (100 mg/day) and clopidogrel
75 mg/day) after procedure and these dual antiplatelets were
aintained at least for 1 year. GP IIbIIIa blocker use was  depend-
nt on physician’s discretion. Thrombus aspiration was done using
hrombuster II catheter (Kaneka, Osaka, Japan) or Export catheter
Medtronic, Minneapolis, MN,  USA) if there were signiﬁcant angi-
graphic visible thrombi in the target lesion before stenting. After
uccessful wiring to the target lesion, predilation was performed
sing 2.0–2.5 mm diameter balloons and then stent was  deployed.
he type of DES was left to the operating physician’s choice. Rou-
ine angiographic follow up was done at six to nine months after
tent implantation.
tudy endpoints
Study endpoints were death (cardiac and non-cardiac deaths),
on-fatal myocardial infarction, repeat revascularization, and com-
osites of major adverse cardiac events (MACEs) at 1 year.
yocardial infarction included Q-wave myocardial infarction and
on-Q-wave myocardial infarction. Revascularization included tar-
et lesion revascularization (TLR), target vessel revascularization
TVR), and non-target vessel revascularization (non-TVR). TLR-lipoprotein; PCI, percutaneous coronary intervention; NSTEMI, non-ST-elevation
myocardial infarction; STEMI, ST-elevation myocardial infarction; UA, unstable
angina.
MACE was  deﬁned as the composite of cardiac death, Q-wave
myocardial infarction and TLR. TVR-MACE was deﬁned as the com-
posite of total death, any myocardial infarction, and TVR. All MACE
(total MACE) was deﬁned as the composite of total death, any
myocardial infarction, and any revascularization (TLR, TVR, and
non-TVR).
At 6–9 months, routine angiographic follow up was strongly rec-
ommended and a variety of angiographic parameters including %
restenosis, restenosis lesion length, binary restenosis, restenosis
type, late loss, and follow up minimal luminal diameter (MLD) were
evaluated between the two groups.
Statistical analysis
All statistical analyses were performed using SPSS 17.0 (Sta-
tistical package for the social sciences, SPSS-PC Inc., Chicago, IL,
USA). Continuous variables were expressed as means ± standard
deviation and were compared using Student’s t-test. Categorical
data were expressed as percentages and were compared using
chi-square statistics or Fisher’s exact test. p-Value of 0.05 was con-
sidered statistically signiﬁcant.
Results
A total 229 patients were enrolled, the mean age was 63.8 years,
and 73.8% (169/229) were male. Twenty-four percent (54/229)
of the patients had IR (HOMA index ≥ 2.5, IR group) and 76%
(175/229) patients were insulin sensitive (HOMA index < 2.5, non-
IR group).
Between the IR and the non-IR groups, there were no signiﬁcant
differences in cardiovascular risk factors including hypertension,
dyslipidemia, and smoking. The concentration of insulin was sig-
niﬁcantly higher in the IR group compared to the non-IR group.
Other laboratory parameters including serum creatinine and indi-
vidual lipid proﬁles were not different between the two groups
except high sensitivity CRP which was  higher in the non-IR group
(Table 1). Regarding the lesion locations, the non-IR group had
I.K. Hwang et al. / Journal of Cardiology 61 (2013) 113–116 115
Table  2
Baseline angiographic and procedural characteristics.
Variable, n (%) IR, n (%) Non-IR, n (%) p-Value
Target vessel 0.168
Left main 3(9.1) 6 (4.3)
RCA 10 (30.3) 33 (23.7)
LAD 11 (33.3) 75 (54.0)
LCX 9 (27.3) 25 (18.0)
Multivessel disease 21 (38.9) 36 (20.6) 0.011
Calciﬁcation 13 (24.1) 28 (16.0) 0.222
Lesion length, mm 24.1 ± 12.0 23.5 ± 9.4 0.384
Stent length, mm 24.3 ± 6.0 23.8 ± 6.3 0.850
Stent diameter, mm 3.1 ± 0.4 3.1 ± 0.4 0.564
Post-stenting MLD  2.9 ± 0.5 3.0 ± 0.5 0.988
Type of stent
SES (Cypher) 16 (29.6) 65 (37.1) 0.334
PES  (Taxus) 15 (27.8) 41 (23.4) 0.587
ZES  (Endeavor) 12 (22.2) 43 (24.6) 0.856
EES  (Xience or Promus) 2 (3.7) 8 (4.6) 1.000
Data are mean ± SD or number (%). IR, insulin resistance; RCA, right coronary artery;
LAD, left anterior descending artery; LCX, left circumﬂex artery; MLD, minimal
luminal diameter; SES, sirolimus-eluting stent; PES, paclitaxel-eluting stent; ZES,
z
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Table 4
Major clinical outcomes at 1 year.
Variable, n (%) IR (n = 54 pts,
23.6%)
Non-IR (n = 175
pts, 76.4%)
p-Value
Total death 3 (5.6) 7 (4.0) 0.704
Cardiac death 1 (1.9) 3 (1.7) 1.000
Non-cardiac death 2 (3.7) 3 (1.7) 0.337
Any  MI  1 (1.9) 2 (1.1) 0.556
NQMI 0 (0.0) 1 (0.6) 1.000
QMI  1 (1.9) 1 (0.6) 0.417
Revascularization 7 (13.0) 13 (7.4) 0.267
CABG 0(0.0) 1 (0.6) 1.000
Repeat PCI 7 (13.0) 12 (6.9) 0.164
TLR  5 (9.3) 8 (4.6) 0.193
TVR  5 (9.3) 9 (5.1) 0.328
Non-TVR 4 (7.4) 7 (4.0) 0.293
TLR-MACE 6 (11.1) 10 (5.7) 0.219
TVR-MACE 8 (14.8) 15 (8.6) 0.198
All-MACE 10 (18.5) 18 (10.3) 0.151
Stent thrombosis 1 (1.9) 1 (0.6) 0.417
Data are mean ± SD or number (%). IR, insulin resistance; MI, myocardial infarc-
otarolimus-eluting stent; EES, everolimus-eluting stent.
ower incidence of multivessel disease as the target vessel (Table 2).
mong the different DESs, sirolimus-eluting stent (SES) was  more
requently implanted in the non-IR group. However, the stent diam-
ter, length, and post-stenting MLD  were not different between the
wo groups (Table 2).
Angiographic outcomes at 6 months demonstrated that there
as a trend toward higher incidence of longer mean restenosis
esion length in the IR group, however other angiographic param-
ters including follow-up MLD, incidence of binary restenosis, late
oss (LL), and mean % in-stent restenosis (>30%) were not different
etween the two groups (Table 3).
The cumulative MACEs up to 1 year were similar between the
wo groups despite numerically higher incidence of composite out-
omes in the IR group [10 patients (18.5%) in the IR Group and 18
atients (10.3%) in the non-IR Group]. There was  1 patient with
ardiac death (1.9%) and 7 patients (13.0%) underwent repeat revas-
ularization in the IR group. There were 3 patients with cardiac
eaths (1.7%) and 13 patients (7.4%) underwent repeat revascu-
arization in the non-IR group. There was no difference in the
ncidence of stent thrombosis up to 1 year between the two groups
Table 4).
The individual clinical endpoints including total deaths, any
yocardial infarction, repeat revascularization, TLR-MACE, and
VR-MACE at 1 year were numerically higher in the IR group except
on-Q-wave myocardial infarction and coronary artery bypass
raft, but those important clinical hard endpoints did not reach
tatistical difference (Table 4).able 3
ix month angiographic outcomes.
Variable, n (%) IR (n = 54 pts,
23.6%)
Non-IR (n = 175
pts, 76.4%)
p-Value
Follow-up MLD  (mm) 2.4 ± 0.9 2.5 ± 0.7 0.198
Restenosis lesion length (mm) 25.4 ± 23.9 22.2 ± 16.8 0.087
Binary restenosis (>50%) 5 (9.3) 8 (4.6) 0.193
Late loss (mm) 0.6 ± 0.8 0.6 ± 0.6 0.175
In-stent restenosis (>30%)a 8 (14.8) 34 (19.4) 0.548
ata are mean ± SD or number (%). IR, insulin resistance; MLD, minimal luminal
iameter.
a In-stent restenosis means more than 30% of restenosis.tion; NQMI, non-Q-wave myocardial infarction; CABG, coronary artery bypass graft;
PCI, percutaneous coronary intervention; TLR, target lesion revascularization; TVR,
target vessel revascularization; MACE, major adverse cardiac events.
Discussion
In this study, baseline clinical and procedural characteristics
were similar between the two groups, except higher incidence of
high sensitivity CRP and the left anterior descending artery as the
target vessel.
At 6 months routine angiographic follow up, there was a trend
toward longer mean restenosis lesion length in the IR group.
However, this worse mid-term angiographic outcome was not
translated into worse 1-year clinical outcomes in the IR group.
IR plays a crucial role in the pathogenesis of type 2 diabetes
mellitus and also in the development of metabolic disorders accom-
panied by obesity, dyslipidemia, impaired glucose tolerance, and
hypertension. IR is known to be closely associated with various
cardiovascular disorders [7–15].
The mechanism how IR predisposes individuals to cardiovascu-
lar disease is explained by the development of metabolic syndrome.
IR leads to hyperglycemia by abnormal glucose metabolism, and
hyperinsulinemia results from elevated levels of blood sugar caus-
ing hypertension, low concentration of HDL-cholesterol, and high
concentration of serum triglyceride [16–19].  Further, IR has been
shown to reduce ﬂow-mediated vasodilation of the brachial artery,
cause endothelial dysfunction, trigger inﬂammatory signaling,
increase the formation of advanced glycation end products, and
increase mean platelet volume [13,20–23].
Many previous studies have demonstrated that IR is associ-
ated with the development of coronary atherosclerosis, plaque
instability, and cardiovascular events in patients with or without
type 2 diabetes, and hyperinsulinemia was only an indirect indi-
cator for insulin sensitivity and related to cardiovascular disease
[14,15,24].
There have been efforts to prove an association between
IR and cardiovascular mortality or coronary atherosclerosis on
coronary angiography based on hyperinsulinemia as an insulin
sensitivity marker [7,14,18,19,25,26].  On the one hand, IR mea-
sured by HOMA models is shown to be related with coronary
atherosclerosis and restenosis following PCI in non-diabetic
patients [3,25–27].IR as assessed by HOMA index was helpful in the early pro-
gnostic stratiﬁcation, and represented an independent predictor
of in-hospital mortality in non-diabetic patients with acute ST-
elevation myocardial infarction undergoing primary PCI [28]. Yun
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[
[
[16 I.K. Hwang et al. / Journal o
t al. analyzed 98 consecutive non-diabetic patients who under-
ent elective coronary angioplasty, and revealed that IR (HOMA
ndex ≥ 2.6) was an independent predictor of in-hospital and 30-
ay MACE rates [29].
Therefore we conducted a study to evaluate the impact of IR
n 6-month angiographic outcomes and 1-year clinical outcomes
n non-diabetic coronary artery disease patients undergoing PCI
n the DES era. Our study demonstrated that IR, as assessed by
OMA index, was not relatively uncommon (29%) in a series of
ll comers based in real-world clinical practice in Korea. Our study
howed that the IR group showed worse angiographic outcomes
t 6 months, suggesting more extensive and severe atherosclerotic
hanges in the target lesions even after the DES implantation in
on-diabetic patients underwent PCI with DESs in real world clini-
al practice as compared with those of the non-IR group. However,
hese angiographic results were not translated into differences in
ajor clinical outcomes at 1 year, probably due to less chance
f recurrence following DES implantation, inherent limitation by
aseline differences in retrospective analysis, relatively small study
opulation, and shorter period of clinical follow up. Our study
esults are hypothesis-generating in the DES era and further ran-
omized clinical study with larger study population with long-term
linical follow up will be needed to make the ﬁnal conclusion.
urther, assessment of clinical outcomes by subanalysis accord-
ng to different subgroups comprising different risk factors and
cute coronary syndromes would be needed with a larger study
opulation to get more detailed information.
tudy limitations
Although the major clinical outcomes were not different
etween the two groups, with a larger study population, more
rolonged follow up may  lead to different results. Because of the
ollowing contributing factors, this result can be a hypothesis-
enerating message and we need more data to make a ﬁnal
onclusion. First, there were different baseline angiographic and
rocedural characteristics due to the limitation of retrospective
nalysis, speciﬁcally a trend toward higher chance of multivessel
isease in the IR group. Second, we did not evaluate important base-
ine characteristics associated with IR such as body mass index and
aist circumference. Third, 6-month angiographic outcomes in the
R group tended to be worse and these ﬁndings may  lead to clinical
ifferences with a larger study population and extended clinical
ollow up. Fourth, all the study population underwent PCI with
ESs and this will limit the recurrence of target lesions and may
ontribute to minimizing the development of differences in major
linical outcomes in both groups.
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